# Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years

> **NCT06216093** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **EuBiologics Co.,Ltd** · enrollment: 100 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections
- Respiratory Syncytial Virus (RSV)

## Interventions

- **BIOLOGICAL:** EuRSV
- **OTHER:** Placebo Comparator

## Key facts

- **NCT ID:** NCT06216093
- **Lead sponsor:** EuBiologics Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-08
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-09-30
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06216093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06216093, "Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06216093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*